Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mercaptopurine

Mercaptopurine Reactions 1704, p237 - 2 Jun 2018 Hepatotoxicity, aching limbs and exercise intolerance: 2 case reports In a case series, a 21-month-old boy and a 10-year-old girl were described, of whom, the boy developed aching limbs and exercise intolerance while the girl developed hepatic toxicity following treatment with mercaptopurine [6-Mercaptopurine] [routes not stated, not all dosages and durations of treatments to reactions onsets stated]. Patient 2: The boy, who had acute lymphoblastic leukaemia, received mercaptopurine. His dose was gradually increased but at higher doses, he developed symptoms of aching limbs and exercise intolerance. Consequently, he was switched to tioguanine [6-thioguanine] and his muscular symptoms resolved. Patient 3 : The girl, who had acute lymphoblastic leukaemia, received mercaptopurine. Subsequently, she developed recurrent episodes of conjugated hyperbilirubinaemia after one month of initiating mercaptopurine therapy. Four months later, she was hospitalised due to deranged coagulation, hypoglycaemia and hepatic encephalopathy. A liver biopsy revealed hepatocyte ballooning and moderate cholestasis. These findings were consistent with mercaptopurine induced hepatotoxicity. Thereafter, the girl received supportive management and her liver function recovered. Her mercaptopurine therapy was switched to tioguanine [6-thioguinine]. Author comment: "During maintenance 6MP metabolites were persistently subtherapeutic but [Mercaptopurine] dose escalation was limited by symptoms http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Mercaptopurine

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Mercaptopurine

Abstract

Reactions 1704, p237 - 2 Jun 2018 Hepatotoxicity, aching limbs and exercise intolerance: 2 case reports In a case series, a 21-month-old boy and a 10-year-old girl were described, of whom, the boy developed aching limbs and exercise intolerance while the girl developed hepatic toxicity following treatment with mercaptopurine [6-Mercaptopurine] [routes not stated, not all dosages and durations of treatments to reactions onsets stated]. Patient 2: The boy, who had acute lymphoblastic leukaemia,...
Loading next page...
 
/lp/springer_journal/mercaptopurine-y5809ldvIe

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46880-0
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p237 - 2 Jun 2018 Hepatotoxicity, aching limbs and exercise intolerance: 2 case reports In a case series, a 21-month-old boy and a 10-year-old girl were described, of whom, the boy developed aching limbs and exercise intolerance while the girl developed hepatic toxicity following treatment with mercaptopurine [6-Mercaptopurine] [routes not stated, not all dosages and durations of treatments to reactions onsets stated]. Patient 2: The boy, who had acute lymphoblastic leukaemia, received mercaptopurine. His dose was gradually increased but at higher doses, he developed symptoms of aching limbs and exercise intolerance. Consequently, he was switched to tioguanine [6-thioguanine] and his muscular symptoms resolved. Patient 3 : The girl, who had acute lymphoblastic leukaemia, received mercaptopurine. Subsequently, she developed recurrent episodes of conjugated hyperbilirubinaemia after one month of initiating mercaptopurine therapy. Four months later, she was hospitalised due to deranged coagulation, hypoglycaemia and hepatic encephalopathy. A liver biopsy revealed hepatocyte ballooning and moderate cholestasis. These findings were consistent with mercaptopurine induced hepatotoxicity. Thereafter, the girl received supportive management and her liver function recovered. Her mercaptopurine therapy was switched to tioguanine [6-thioguinine]. Author comment: "During maintenance 6MP metabolites were persistently subtherapeutic but [Mercaptopurine] dose escalation was limited by symptoms

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.